Ryan J. Hansen

3.2k total citations · 1 hit paper
65 papers, 2.5k citations indexed

About

Ryan J. Hansen is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Ryan J. Hansen has authored 65 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 12 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Oncology. Recurrent topics in Ryan J. Hansen's work include Monoclonal and Polyclonal Antibodies Research (10 papers), DNA Repair Mechanisms (6 papers) and Platelet Disorders and Treatments (5 papers). Ryan J. Hansen is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), DNA Repair Mechanisms (6 papers) and Platelet Disorders and Treatments (5 papers). Ryan J. Hansen collaborates with scholars based in United States, Australia and Denmark. Ryan J. Hansen's co-authors include Joseph P. Balthasar, Evelyn D. Lobo, Daniel L. Gustafson, Lev N. Zakharov, Michael D. Pluth, Jasmine Davda, Leticia Montoya, Paul J. Lunghofer, Michael M. Haley and Darren W. Johnson and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Journal of Clinical Oncology.

In The Last Decade

Ryan J. Hansen

64 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antibody Pharmacokinetics and Pharmacodynamics

2004 688 citations Evelyn D. Lobo, Ryan J. Hansen et al. Journal of Pharmaceutical Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryan J. Hansen United States	23	918	622	505	410	212	65	2.5k
Akinobu Hamada Japan	36	1.2k 1.3×	365 0.6×	417 0.8×	1.6k 3.9×	351 1.7×	178	3.7k
Michel Vidal France	31	1.6k 1.7×	380 0.6×	239 0.5×	897 2.2×	207 1.0×	182	3.3k
Carl P. Decicco United States	33	1.3k 1.5×	203 0.3×	239 0.5×	772 1.9×	169 0.8×	100	3.4k
Zahid N. Rabbani United States	37	2.8k 3.1×	1.2k 1.9×	417 0.8×	846 2.1×	224 1.1×	78	5.3k
Craig Gedye Australia	28	1.0k 1.1×	339 0.5×	953 1.9×	1.2k 3.0×	68 0.3×	101	3.0k
John P. Fruehauf United States	37	2.1k 2.3×	327 0.5×	370 0.7×	1.4k 3.5×	108 0.5×	100	4.2k
Fang Bai China	33	2.0k 2.2×	290 0.5×	242 0.5×	405 1.0×	127 0.6×	173	3.5k
John M. Sanders United States	37	1.6k 1.7×	297 0.5×	835 1.7×	501 1.2×	203 1.0×	71	4.0k
Yan Gong China	33	1.8k 2.0×	368 0.6×	504 1.0×	627 1.5×	34 0.2×	160	3.3k
Monica Galliano Italy	29	2.3k 2.5×	291 0.5×	163 0.3×	558 1.4×	219 1.0×	103	3.1k

Countries citing papers authored by Ryan J. Hansen

Since Specialization

Citations

This map shows the geographic impact of Ryan J. Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan J. Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan J. Hansen more than expected).

Fields of papers citing papers by Ryan J. Hansen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan J. Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan J. Hansen. The network helps show where Ryan J. Hansen may publish in the future.

Co-authorship network of co-authors of Ryan J. Hansen

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan J. Hansen. A scholar is included among the top collaborators of Ryan J. Hansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan J. Hansen. Ryan J. Hansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maron, Steven B., Manish Sharma, Alexander I. Spira, et al.. (2025). Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications.. Journal of Clinical Oncology. 43(4_suppl). 1 indexed citations

Xu, Haineng, Sarah B. Gitto, Gwo‐Yaw Ho, et al.. (2024). CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience. 27(7). 109978–109978. 4 indexed citations

Moyers, Julie S., Ryan J. Hansen, Jonathan W. Day, et al.. (2022). Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein. Journal of Pharmacology and Experimental Therapeutics. 382(3). 346–355. 41 indexed citations

Ho, Gwo‐Yaw, Holly E. Barker, Cassandra J. Vandenberg, et al.. (2018). SRA737, a novel Chk1 inhibitor, shows efficacy in CCNE1-amplified and MYCN-overexpressing high-grade serous ovarian cancer patient-derived xenograft models. European Journal of Cancer. 103. 1 indexed citations

Briggs, Joseph, Ling Ren, Yien Che Tsai, et al.. (2017). Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus. PLoS ONE. 12(9). e0185089–e0185089. 5 indexed citations

Morrow, James J., Arnulfo Mendoza, Allyson E. Koyen, et al.. (2016). mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo. Clinical Cancer Research. 22(24). 6129–6141. 22 indexed citations

Eacho, Patrick I., Krista Schroeder, Thomas P. Beyer, et al.. (2015). NOVEL MECHANISM FOR THE SUSTAINED DURABILITY OF PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 MONOCLONAL ANTIBODY LY3015014. Journal of the American College of Cardiology. 65(10). A1577–A1577. 3 indexed citations

Schroeder, Krista, Thomas P. Beyer, Ryan J. Hansen, et al.. (2015). Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. Journal of Lipid Research. 56(11). 2124–2132. 22 indexed citations

Clausen, Dane J., Ryan J. Hansen, Paul J. Lunghofer, et al.. (2015). Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. Cancer Chemotherapy and Pharmacology. 75(4). 671–682. 19 indexed citations

10.

Maycotte, Paola, Christy M. Gearheart, Rebecca Barnard, et al.. (2014). STAT3-Mediated Autophagy Dependence Identifies Subtypes of Breast Cancer Where Autophagy Inhibition Can Be Efficacious. Cancer Research. 74(9). 2579–2590. 152 indexed citations

11.

Griffenhagen, Gregg M., Marlis L. Rezende, Daniel L. Gustafson, et al.. (2014). Pharmacokinetics and pharmacodynamics of propofol with or without 2% benzyl alcohol following a single induction dose administered intravenously in cats. Veterinary Anaesthesia and Analgesia. 42(5). 472–483. 11 indexed citations

12.

Spreafico, Anna, John J. Tentler, Todd M. Pitts, et al.. (2013). Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. Clinical Cancer Research. 19(15). 4149–4162. 58 indexed citations

13.

Miranda, Briana R. De, James A. Miller, Ryan J. Hansen, et al.. (2013). Neuroprotective Efficacy and Pharmacokinetic Behavior of Novel Anti-Inflammatory Para-Phenyl Substituted Diindolylmethanes in a Mouse Model of Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics. 345(1). 125–138. 49 indexed citations

14.

Mitchell, Leah, et al.. (2012). Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. International Immunopharmacology. 15(2). 357–363. 24 indexed citations

15.

Diamond, Jennifer R., Bruno R. Bastos, Ryan J. Hansen, et al.. (2010). Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(4). 849–860. 57 indexed citations

16.

Hansen, Ryan J., et al.. (2010). Rapid and sensitive LC–MS/MS method for determination of felbamate in mouse plasma and tissues and human plasma. Journal of Chromatography B. 878(32). 3432–3436. 6 indexed citations

17.

Hansen, Ryan J., Ramamoorthy Nagasubramanian, Shannon M. Delaney, et al.. (2005). Role of O6-Alkylguanine-DNA Alkyltransferase in Protecting against 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-Induced Long-Term Toxicities. Journal of Pharmacology and Experimental Therapeutics. 315(3). 1247–1255. 10 indexed citations

18.

Lobo, Evelyn D., Ryan J. Hansen, & Joseph P. Balthasar. (2004). Antibody Pharmacokinetics and Pharmacodynamics. Journal of Pharmaceutical Sciences. 93(11). 2645–2668. 688 indexed citations breakdown →

19.

Hansen, Ryan J. & Joseph P. Balthasar. (2003). Pharmacokinetic/Pharmacodynamic Modeling of the Effects of Intravenous Immunoglobulin on the Disposition of Antiplatelet Antibodies in a Rat Model of Immune Thrombocytopenia. Journal of Pharmaceutical Sciences. 92(6). 1206–1215. 62 indexed citations

20.

Hansen, Ryan J. & Joseph P. Balthasar. (1999). An ELISA for quantification of murine IgG in rat plasma: application to the pharmacokinetic characterization of AP-3, a murine anti-glycoprotein IIIa monoclonal antibody, in the rat. Journal of Pharmaceutical and Biomedical Analysis. 21(5). 1011–1016. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact